ClinicalTrials.gg
CompletedNCT00415623Updated Feb 11, 2021Results posted

A Comparative Study Between Amlodipine 10mg And 5mg With Hypertension For Whom 5mg Is Insufficient

A Phase 3 interventional study of Amlodipine and Amlodipine in Hypertension, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 15 sites in Japan. Open to participants aged 20 Years to 79 Years. Per ClinicalTrials.gov, last updated 2021-02-11.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
305
Allocation
Randomized
Ages
20 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 187 studies testing amlodipine in Hypertension — 6 open to participants now, 8 under way, 2 of them phase 3. Amlodipine · Hypertension.

Enrollment
68th of 186
305 · median 180
Started
2007
with 16 others
Phase 3
69 of 187
2 open now
Registered
36th of 187
by date
Lead sponsor
6 of 187
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 187 studies testing amlodipine in Hypertension, this one is the 68th largest by enrollment of the 186 interventional ones that give a count, is one of 17 that started in 2007, is one of 69 in phase 3, and was the 36th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.

Browse Hypertension studies →

Open to participants now

6 of the 187 studies testing amlodipine in Hypertension are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About amlodipine

Amlodipine: first FDA approval 1992 (NORVASC), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.

This study: 20 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies testing amlodipine in Hypertension, or all of them as a file.
02

Study summary

The changes in the trough systolic blood pressure from the baseline were assessed after 8 weeks of double-blind treatment with amlodipine 10 mg or amlodipine 5 mg

03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
20 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Untreated Hypertensive Patients: An systolic blood pressure of >=160 mmHg or diastolic blood pressure >=100mmHg.
  • Treated Hypertensive Patients: An systolic blood pressure of >=140 mmHg or diastolic blood pressure of >= 90 mmHg.
  • Patients with insufficient response to 5 mg of amlodipine in the screening period:Two successive systolic blood pressure measurements at Visit 4 (Week -2) and Visit 5 (Week 0 = baseline) >=140 mmHg
  • Patients with a screening treatment compliance rate >= 80%

Exclusion criteria

Exclusion Criteria:

  • Subjects with secondary hypertension (renal disease, pheochromocytoma, and Cushing's syndrome, etc.), severe hypertension (systolic blood pressure of 180 mmHg or higher, or diastolic blood pressure of 110 mmHg or higher), and malignant hypertension
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
305 participants (actual)

Study arms

  • Active comparator
    Amlodipine 5mg

    Drug: Amlodipine

  • Experimental
    Amlodipine 10mg

    Drug: Amlodipine

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Systolic Blood Pressure (SBP) From Baseline to Week 8

    Mean change in the trough SBP

    Time frame: Baseline to Week 8

Secondary outcomes

  1. Change in Diastolic Blood Pressure (DBP) From Baseline to Week 8

    Mean change in the trough DBP

    Time frame: Baseline to Week 8

  2. Combined Mean Change in SBP From Baseline to Week 6 and Week 8 (Mean by Patient)

    Arithmetic mean of Week 6 \& Week 8 by patient for "Change from baseline in SBP at Week 6" and "Change from baseline in SBP at Week 8"

    Time frame: Baseline to Week 6 and Week 8

  3. Combined Mean Change in DBP From Baseline to Week 6 and Week 8 (Mean by Patient)

    Arithmetic mean of Week 6 \& Week 8 by patient for "Change from baseline in DBP at Week 6" and "Change from baseline in DBP at Week 8"

    Time frame: Baseline to Week 6 and Week 8

  4. Number of Subjects Achieving the Target Blood Pressure Reduction Value at Week 8

    Target blood pressure reduction value based on Japan Society of Hypertension Guidelines for the Management of Hypertension 2004: SBP below 130 mmHg and DBP below 85 mmHg for \<=64 years old; SBP below 140 mmHg and DBP below 90 mmHg for \>=65 years old

    Time frame: Week 8

  5. Combined Number of Subjects Achieving the Target Blood Pressure Reduction Value at Both Weeks 6 and 8

    Target blood pressure reduction value based on Japan Society of Hypertension Guidelines for the Management of Hypertension 2004: SBP below 130 mmHg and DBP below 85 mmHg for \<=64 years old; SBP below 140 mmHg and DBP below 90 mmHg for \>=65 years old

    Time frame: Week 6 and Week 8

  6. Number of Subjects Achieving the Target Blood Pressure Reduction Value and Whose SBP Decreased From Baseline by >= 10 mmHg at Week 8

    Target blood pressure reduction value based on Japan Society of Hypertension Guidelines for the Management of Hypertension 2004: SBP below 130 mmHg and DBP below 85 mmHg for \<=64 years old; SBP below 140 mmHg and DBP below 90 mmHg for \>=65 years old

    Time frame: Week 8

  7. Combined Number of Subjects Achieving the Target Blood Pressure Reduction Value and Whose SBP Decreased From Baseline by >= 10 mmHg at Both Weeks 6 and 8

    Target blood pressure reduction value based on Japan Society of Hypertension Guidelines for the Management of Hypertension 2004: SBP below 130 mmHg and DBP below 85 mmHg for \<=64 years old; SBP below 140 mmHg and DBP below 90 mmHg for \>=65 years old

    Time frame: Week 6 and Week 8

  8. Trough Plasma Concentrations of Amlodipine -Amlodipine 5 mg

    Time frame: Baseline, Week 4 and Week 8

  9. Trough Plasma Concentrations of Amlodipine -Amlodipine 10 mg

    Time frame: Baseline, Week 4, and Week 8

07

Results

Posted Dec 9, 2008

Participant flow

Twenty-four (24) centers in Japan

Participant flow — Overall Study
MilestoneAmlodipine 5 mgAmlodipine 10 mg
Started154151
Completed149146
Not completed55
Withdrew: Adverse event34
Withdrew: Death10
Withdrew: Withdrawal by subject11

Outcome measures

PrimaryChange in Systolic Blood Pressure (SBP) From Baseline to Week 8

Mean change in the trough SBP

Time frame:
Baseline to Week 8
Reported as:
Least squares mean · mmHg
Change in Systolic Blood Pressure (SBP) From Baseline to Week 8
mmHgAmlodipine 5 mgAmlodipine 10 mg
Change in Systolic Blood Pressure (SBP) From Baseline to Week 8-7.0 (-8.8 to -5.2)-13.7 (-15.4 to -12.0)
Statistical analysis
  • Amlodipine 5 mg vs Amlodipine 10 mg · ANCOVA · p = <0.001 · Mean difference (final values): -6.7 · 95% CI -9.0 to -4.4
SecondaryChange in Diastolic Blood Pressure (DBP) From Baseline to Week 8

Mean change in the trough DBP

Time frame:
Baseline to Week 8
Reported as:
Least squares mean · mmHg
Change in Diastolic Blood Pressure (DBP) From Baseline to Week 8
mmHgAmlodipine 5 mgAmlodipine 10 mg
Change in Diastolic Blood Pressure (DBP) From Baseline to Week 8-2.7 (-3.9 to -1.4)-6.8 (-8.0 to -5.5)
Statistical analysis
  • Amlodipine 5 mg vs Amlodipine 10 mg · ANCOVA · p = <0.001 · Mean difference (final values): -4.1 · 95% CI -5.7 to -2.5
SecondaryCombined Mean Change in SBP From Baseline to Week 6 and Week 8 (Mean by Patient)

Arithmetic mean of Week 6 \& Week 8 by patient for "Change from baseline in SBP at Week 6" and "Change from baseline in SBP at Week 8"

Time frame:
Baseline to Week 6 and Week 8
Reported as:
Least squares mean · mmHg
Combined Mean Change in SBP From Baseline to Week 6 and Week 8 (Mean by Patient)
mmHgAmlodipine 5 mgAmlodipine 10 mg
Combined Mean Change in SBP From Baseline to Week 6 and Week 8 (Mean by Patient)-6.8 (-8.4 to -5.2)-13.9 (-15.5 to -12.4)
Statistical analysis
  • Amlodipine 5 mg vs Amlodipine 10 mg · ANCOVA · p = <0.001 · Mean difference (final values): -7.1 · 95% CI -9.1 to -5.1
SecondaryCombined Mean Change in DBP From Baseline to Week 6 and Week 8 (Mean by Patient)

Arithmetic mean of Week 6 \& Week 8 by patient for "Change from baseline in DBP at Week 6" and "Change from baseline in DBP at Week 8"

Time frame:
Baseline to Week 6 and Week 8
Reported as:
Least squares mean · mmHg
Combined Mean Change in DBP From Baseline to Week 6 and Week 8 (Mean by Patient)
mmHgAmlodipine 5 mgAmlodipine 10 mg
Combined Mean Change in DBP From Baseline to Week 6 and Week 8 (Mean by Patient)-2.5 (-3.6 to -1.4)-6.5 (-7.6 to -5.5)
Statistical analysis
  • Amlodipine 5 mg vs Amlodipine 10 mg · ANCOVA · p = <0.001 · Mean difference (final values): -4.0 · 95% CI -5.4 to -2.6
SecondaryNumber of Subjects Achieving the Target Blood Pressure Reduction Value at Week 8

Target blood pressure reduction value based on Japan Society of Hypertension Guidelines for the Management of Hypertension 2004: SBP below 130 mmHg and DBP below 85 mmHg for \<=64 years old; SBP below 140 mmHg and DBP below 90 mmHg for \>=65 years old

Time frame:
Week 8
Reported as:
Number · participants
Number of Subjects Achieving the Target Blood Pressure Reduction Value at Week 8
participantsAmlodipine 5 mgAmlodipine 10 mg
Number of Subjects Achieving the Target Blood Pressure Reduction Value at Week 84366
Statistical analysis
  • Amlodipine 5 mg vs Amlodipine 10 mg · Regression, Logistic · p = 0.002 · Odds ratio (or): 2.33 · 95% CI 1.36 to 3.99
SecondaryCombined Number of Subjects Achieving the Target Blood Pressure Reduction Value at Both Weeks 6 and 8

Target blood pressure reduction value based on Japan Society of Hypertension Guidelines for the Management of Hypertension 2004: SBP below 130 mmHg and DBP below 85 mmHg for \<=64 years old; SBP below 140 mmHg and DBP below 90 mmHg for \>=65 years old

Time frame:
Week 6 and Week 8
Reported as:
Number · participants
Combined Number of Subjects Achieving the Target Blood Pressure Reduction Value at Both Weeks 6 and 8
participantsAmlodipine 5 mgAmlodipine 10 mg
Combined Number of Subjects Achieving the Target Blood Pressure Reduction Value at Both Weeks 6 and 82252
Statistical analysis
  • Amlodipine 5 mg vs Amlodipine 10 mg · Regression, Logistic · p = <0.001 · Odds ratio (or): 4.46 · 95% CI 2.28 to 8.74
SecondaryNumber of Subjects Achieving the Target Blood Pressure Reduction Value and Whose SBP Decreased From Baseline by >= 10 mmHg at Week 8

Target blood pressure reduction value based on Japan Society of Hypertension Guidelines for the Management of Hypertension 2004: SBP below 130 mmHg and DBP below 85 mmHg for \<=64 years old; SBP below 140 mmHg and DBP below 90 mmHg for \>=65 years old

Time frame:
Week 8
Reported as:
Number · participants
Number of Subjects Achieving the Target Blood Pressure Reduction Value and Whose SBP Decreased From Baseline by >= 10 mmHg at Week 8
participantsAmlodipine 5 mgAmlodipine 10 mg
Number of Subjects Achieving the Target Blood Pressure Reduction Value and Whose SBP Decreased From Baseline by >= 10 mmHg at Week 83561
Statistical analysis
  • Amlodipine 5 mg vs Amlodipine 10 mg · Regression, Logistic · p = 0.001 · Odds ratio (or): 2.55 · 95% CI 1.50 to 4.36
SecondaryCombined Number of Subjects Achieving the Target Blood Pressure Reduction Value and Whose SBP Decreased From Baseline by >= 10 mmHg at Both Weeks 6 and 8

Target blood pressure reduction value based on Japan Society of Hypertension Guidelines for the Management of Hypertension 2004: SBP below 130 mmHg and DBP below 85 mmHg for \<=64 years old; SBP below 140 mmHg and DBP below 90 mmHg for \>=65 years old

Time frame:
Week 6 and Week 8
Reported as:
Number · participants
Combined Number of Subjects Achieving the Target Blood Pressure Reduction Value and Whose SBP Decreased From Baseline by >= 10 mmHg at Both Weeks 6 and 8
participantsAmlodipine 5 mgAmlodipine 10 mg
Combined Number of Subjects Achieving the Target Blood Pressure Reduction Value and Whose SBP Decreased From Baseline by >= 10 mmHg at Both Weeks 6 and 81644
Statistical analysis
  • Amlodipine 5 mg vs Amlodipine 10 mg · Regression, Logistic · p = <0.001 · Odds ratio (or): 4.16 · 95% CI 2.12 to 8.19
SecondaryTrough Plasma Concentrations of Amlodipine -Amlodipine 5 mg
Time frame:
Baseline, Week 4 and Week 8
Reported as:
Geometric mean · ng/mL
Trough Plasma Concentrations of Amlodipine -Amlodipine 5 mg
ng/mLBaselineWeek 4Week 8
Trough Plasma Concentrations of Amlodipine -Amlodipine 5 mg7.02 (6.5 to 7.5)6.83 (6.3 to 7.4)7.03 (6.6 to 7.5)
SecondaryTrough Plasma Concentrations of Amlodipine -Amlodipine 10 mg
Time frame:
Baseline, Week 4, and Week 8
Reported as:
Geometric mean · ng/mL
Trough Plasma Concentrations of Amlodipine -Amlodipine 10 mg
ng/mLBaselineWeek 4Week 8
Trough Plasma Concentrations of Amlodipine -Amlodipine 10 mg7.18 (6.7 to 7.7)16.9 (15.7 to 18.1)16.9 (15.7 to 18.2)

Baseline characteristics

Age, Customized
Age, Customized(partcipants)Amlodipine 5 mgAmlodipine 10 mgTotal
< 20 years000
20 to 44 years151530
45 to 64 years7570145
>= 65 years6466130
Sex: Female, Male
Sex: Female, Male(Participants)Amlodipine 5 mgAmlodipine 10 mgTotal
Female7059129
Male8492176
Region of Enrollment
Region of Enrollment(participants)Amlodipine 5 mgAmlodipine 10 mgTotal
Japan154151305
08

Study locations

15 sites
  • Pfizer Investigational Site
    Kasuya-gun, Fujuoka, Japan
  • Pfizer Investigational Site
    Chikushino, Fukuoka, Japan
  • Pfizer Investigational Site
    Kitakyushu, Fukuoka, Japan
  • Pfizer Investigational Site
    Koga, Fukuoka, Japan
  • Pfizer Investigational Site
    Sapporo, Hokkaidou, Japan
  • Pfizer Investigational Site
    Sapporo, Hokkaido, Japan
  • Pfizer Investigational Site
    Yokohama, Kanagawa, Japan
  • Pfizer Investigational Site
    Iruma, Saitama, Japan
  • Pfizer Investigational Site
    Koshigaya, Saitama, Japan
  • Pfizer Investigational Site
    Adachi-ku, Tokyo, Japan
  • Pfizer Investigational Site
    Edogawa-ku, Tokyo, Japan
  • Pfizer Investigational Site
    Meguro-ku, Tokyo, Japan
  • Pfizer Investigational Site
    Setagaya-ku, Tokyo, Japan
  • Pfizer Investigational Site
    Sumida, Tokyo, Japan
  • Pfizer Investigational Site
    Fukuoka, Japan
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2007, a primary completion of Oct 2007 and a completion of Oct 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2008, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2006
First posted
Dec 25, 2006
Start
Jan 2007
Primary completionActual
Oct 2007
CompletionActual
Oct 2007
Results first posted
Dec 9, 2008
Last update
Feb 11, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00415623
Responsible party
Sponsor
First posted
Dec 25, 2006
Start date
Jan 2007
Primary completion
Oct 2007
Completion
Oct 2007
Results posted
Dec 9, 2008
Last update
Feb 11, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amlodipine

Start the discussion